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Abstract
Motivation: Transcriptome-based computational drug repurposing has attracted considerable
interest by bringing about faster and more cost-effective drug discovery. Nevertheless, key limita-
tions of the current drug connectivity-mapping paradigm have been long overlooked, including the
lack of effective means to determine optimal query gene signatures.
Results: The novel approach Dr Insight implements a frame-breaking statistical model for the
‘hand-shake’ between disease and drug data. The genome-wide screening of concordantly
expressed genes (CEGs) eliminates the need for subjective selection of query signatures, added to
eliciting better proxy for potential disease-specific drug targets. Extensive comparisons on simu-
lated and real cancer datasets have validated the superior performance of Dr Insight over several
popular drug-repurposing methods to detect known cancer drugs and drug–target interactions. A
proof-of-concept trial using the TCGA breast cancer dataset demonstrates the application of Dr
Insight for a comprehensive analysis, from redirection of drug therapies, to a systematic construc-
tion of disease-specific drug-target networks.
Availability and implementation: Dr Insight R package is available at https://cran.r-project.org/web/
packages/DrInsight/index.html.
Contact: Jinghua.Gu@BSWHealth.org
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Computational drug repurposing has recently gained increasing
popularity in modern pharmacogenomic studies. Large-scale drug-
perturbed gene expression datasets, such as Connectivity Map
(CMap) (Lamb et al., 2006; Subramanian et al., 2017), provide un-
precedented opportunities for prioritizing treatments based on the
associations between disease state and chemical intervention.
Numerical computational approaches have been developed, taking
full advantage of these high-throughput resources, for in silico pre-
diction of disease–drug connectivity and drug–drug connectivity (El-
Hachem et al., 2017; Hameed et al., 2018; Iorio et al., 2010, 2013;
Lee et al., 2016a; Peyvandipour et al., 2018; Sirota et al., 2011).
Notable successes have been achieved using CMap and its variants
to uncover novel therapeutic redirections of existing drugs to treat
various types of diseases, including obesity (Lee et al., 2016b; Liu
et al., 2015a), neurodegenerative diseases (Sandor et al., 2017;
Siavelis et al., 2016), gastrointestinal and liver diseases (Hicks et al.,
2017), stroke and sepsis (Chen et al., 2015b) and cancers (Hsieh
et al., 2016; Liu et al., 2015b; Xiang et al., 2016; Zhao et al., 2016).
It is worth noting that the rapid growth of computational drug dis-
covery also reflects a paradigm shift in pharmacogenomics research:
from the conventional pursuit of a ‘magic bullet’ that targets a single
‘disease-causing’ gene, to the emerging polypharmacology
approaches that examine disease–drug–gene interactions at the sys-
tem and network level.
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Despite a promising first step, systematic delineation of disease-
specific drug–gene interactions has continued to challenge the cur-
rent statistical framework, leaving significant computational poten-
tial on the table. Conventional drug-repurposing methods follow a
two-step model to identify drugs that reverse disease phenotypes.
First, a list of signature genes is compiled based on the disease data-
set. One widely adopted approach is to use statistical tests (e.g. dif-
ferential gene expression analysis) to prioritize the genes by their
ability to differentiate phenotypic changes in the disease data. Then
the top and bottom ranked genes are selected for CMap query. Once
a signature has been created, the second step is to perform enrich-
ment analysis comparing this signature to the drug-perturbed ex-
pression profiles from the reference dataset for drug prioritization.
As far as the performance of drug repurposing is concerned, the
two-step paradigm is limited in the following ways. In practice, it is
very difficult to determine the optimal query signature. Surprisingly,
choices of the signature criteria and size vary drastically from one
study to another in real applications, as shown in Supplementary
Table S1 (Musa et al., 2017). For example, in a central nervous sys-
tem (CNS) injury study, 21 genes were selected as a signature based
on a P-value threshold of 0.05 and absolute fold change 1.5, com-
pared with a glioblastoma (GBM) study where 1000 genes were
used for drug analysis based on a P-value threshold of 0.0001 and
absolute fold change 4. Although adaptations have been reported
to tackle this issue by intensively iterating through hundreds or even
thousands of possible signature size configurations to select the best
parameter based on certain objective functions, their efficacy in a
real-word application has yet to be adequately demonstrated. Aside
from the excessive computational overhead, the utility of these rem-
edies is limited either due to the requirement of external information
(e.g. known FDA-approved drugs) or the proposed procedure is
merely an ad hoc solution with no guarantee that the target criteria
can even be achieved (Shigemizu et al., 2012; Wen et al., 2016).
Another limitation of the two-step model is that, because the signa-
tures include a limited number of genes determined solely from the
disease dataset, the genes that are differentially expressed in the
drug-perturbed expression data with informative importance may
be overlooked. Therefore, enrichment analysis based on a non-
optimized signature with arbitrary size not only creates a big hurdle
for accurate modeling of disease–drug association, but also compro-
mises genome-wide, systematic investigation of drug–target
interactions.
To overcome the above-mentioned limitations in developing a
much improved and system-wide examination of the associations
between diseases, drugs and genes, we developed a novel computa-
tional framework called Dr Insight (Drug Repurposing: Integration
and Systematic Investigation of Genomic High-Throughput data).
Unlike the conventional two-step model, Dr Insight employs order
statistics to directly measure the concordance (e.g. inverse associ-
ation) between the disease data and drug-perturbed data for each in-
dividual gene. Concordantly expressed genes (CEGs) are elicited as
features to further formulate an outlier sum statistic for drug ana-
lysis. Dr Insight has several unique advantages compared to the
existing methods: (i) Dr Insight completely eliminates the need for
users to provide a fixed-sized gene signature derived from the disease
dataset, which allows automated, signature-free drug query. (ii) For
the first time, the order statistics offer a robust statistical evaluation
of the concordance of gene expression change in both disease and
drug profiles. Compared with the conventional model of using only
differentially expressed genes (DEGs) as signatures to calculate the
drug connectivity, statistically significant CEGs construct an
improved set of features that represent potential drug targets with
inverted expression in the disease dataset. (iii) Whereas drug-target
detection in the conventional framework is typically limited to
around a dozen to a few hundred genes, Dr Insight has expanded
the search of potential drug targets to the entire transcriptome.
Dr Insight empowers genome-wide drug-target analysis with an in-
depth examination of drug modes of action (MoA) at the pathway
and network level. A feature comparison of Dr Insight with several
popular signature-based drug-repurposing methods, including
CMap (Lamb et al., 2006), sscMap (Zhang and Gant, 2009),
NFFinder (Setoain et al., 2015) and Cogena (Jia et al., 2016), is
listed in Supplementary Table S2.
To demonstrate the advantage of this new drug-repurposing
framework, we applied Dr Insight to both simulated datasets as
well as three cancer datasets and two non-cancer datasets
(Supplementary Material S1.1 and Supplementary Table S3) and
compared it against the four signature-based methods. We showed
that Dr Insight, without the need to tune the signature size, per-
formed better than previous signature-based methods at detecting
known drugs (FDA-approved or in advanced clinical trials, see
Supplementary Material S1.2 and Supplementary Table S4 for
details) in both simulation and real data. Using data collected from
drug target databases such as the Search Tool for Interactions of
Chemicals (STITCH) (Kuhn et al., 2008) and the Comparative
Toxicogenomics Database (CTD) (Davis et al., 2009)
(Supplementary Material S1.3), we further illustrated the exception-
al performance of Dr Insight for drug target prediction by validating
that the CEGs detected were statistically more enriched in known
drug–target interactions compared with DEGs. Finally, we used the
TCGA breast cancer dataset as a case study to demonstrate that Dr
Insight was not only a powerful tool for novel re-direction of breast
cancer drugs, but also provided unbiased, systematic prediction of
potential drug target pathways to facilitate mechanistic understand-
ing of disease–drug interactions.
2 Materials and methods
Dr Insight completely shifts the computational framework from the
conventional signature-based enrichment analysis to a genome-
wide, disease-drug concordance alignment. Figure 1 gives the princi-
pal workflow of Dr Insight. Instead of extracting a list of significant-
ly up- and down-regulated signature genes based on differential gene
expression analysis, Dr Insight uses order statistics to combine infor-
mation from disease data and drug-perturbed expression data
(Fig. 1A). Such a ‘handshake’ between the two parts of the data
allows a systematic portrait of the drug connectivity at the finest
resolution: for each individual gene, the order statistic gives a quan-
titative measure of its connectivity between the disease and drug
profiles. As an important feature selection step, genes with statistic-
ally significant connectivity are elicited as CEGs, which comprehen-
sively include genes that are concordantly expressed in both disease
and drug-perturbed expression data without depending on a pre-
defined DEG selection criteria (Fig. 1B). The CEGs are further
pooled together to calculate an overall connectivity score for each
individual drug based on an outlier-sum method (Gu et al., 2012;
Tibshirani and Hastie, 2007) to test drug treatment effect (Fig. 1C).
Finally, in combination with several external gene set databases
such as Gene Ontology (GO) (Ashburner et al., 2000), Kyoto
Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto,
2000) and NCI Pathway Interaction Database (PID) (Schaefer et al.,
2009), the drug–CEG interactions serve as the skeleton to assemble
disease-specific drug-target interaction networks (Fig. 1D and E).
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2.1 Global investigation of concordant gene expression
The input for Dr Insight is a complete rank list of all genes based on
differential gene expression analysis between case and control sam-
ples (e.g. tumor versus normal). In a disease study, we are typically
interested in whether the drug under investigation shows potential
treatment effect (i.e. negative connectivity) or adverse effect (posi-
tive connectivity) with respect to a given disease profile. When inves-
tigating treatment effect, a gene is deemed ‘concordantly expressed’
if it is inversely expressed between the disease data and the reference
drug data. In other words, a CEG should be up-regulated in the dis-
ease data but down-regulated after drug perturbation, and vice
versa. On the other hand, a CEG in the drug adverse effect model
should display positive correlation as being either up- or down-
regulated in both disease data and drug data.
For gene g ð1  g  NÞ, we denote its scaled rank (the original
rank scaled by the total number of genes N) in the disease data X
and the ith drug instance Yi (i.e. instance from CMap, see
Supplementary Abbreviations and Terminologies for definition)
as rg;X and rg;Yi ; respectively, where
1
N  rg;X  1, 1N  rg;Yi  1. In
the case of a drug treatment effect study, the ranks are inversely
ordered in disease and drug data (i.e. large-scaled rank
rg;X represents up-regulation of gene expression in the disease
phenotype, while large-scaled rank rg;Yi represents that gene g is
down-regulated in drug instance Yi). In this work, we only focus on
finding drugs that can reverse the disease status back to normal
(treatment effect), although this concept can be easily generalized to
investigate adverse effect of drugs. For concordant gene expression,
two patterns are defined when studying drug treatment effect:
1. Type 1 concordant expression: gene g is up-regulated in the dis-
ease phenotype and down-regulated after drug perturbation;
2. Type 2 concordant expression: gene g is down-regulated in the
disease phenotype and up-regulated after drug perturbation.
2.2 Detection of concordantly expressed genes using
order statistic
To model type 1 concordance of gene g between disease data X and
drug instance Yi, we calculate the minimum statistic (smallest order
statistic) as follows:
rming;i ¼ min rg;X; rg;Yið Þ: (1)
rming;i is a non-parametric statistic measuring whether gene g has large
ranks in both the disease data (up-regulation) and reference drug
data (down-regulation). A large rming;i value indicates that gene g has
strong type 1 concordance, in which case a right-tailed test is appro-
priate. Under the null hypotheses H0 that rg;X and rg;Yi are independ-
ent rank values, the one-sided P-value for rming;i in a right-tailed test is
given by:
P rming;i  r
H0  ¼ 1  P rming;i  r 1N
H0
!
¼ 1  Ir1N 1; 2ð Þ;
(2)
where Ir1N is the regularized incomplete Beta function (see the proof
of Theorem 1 in Supplementary Material S2).
Similarly, we use the maximum statistic (largest order statistic):
rmaxg;i ¼ maxðrg;X; rg;Yi Þ; (3)
to model type 2 concordance. A smaller rmaxg;i gives stronger evidence
that gene g is down-regulated in the disease data and up-regulated
upon drug perturbation, hence suggesting the use of a left-tailed test.
According to Theorem 2 (Supplementary Material S2), the one-
sided P-value for rmaxg;i in a left-tailed test is given by:
P rmaxg;i  r jH0
  ¼ Ir 2; 1ð Þ: (4)
Statistically significant genes (P-value0:05) derived from min-
imum and maximum statistics are referred to as type 1 or type 2
CEGs, respectively, which will be later utilized as key features for
downstream drug repurposing analysis. We also comprehensively
assessed Dr Insight’s performance with a series of P-value cut-offs
on five disease datasets, including three cancer and two non-cancer
datasets, and confirmed that the recommended 0.05 thresholds had
robust performance across all applications (Supplementary Material
S3, Supplementary Fig. S1).
2.3 Modeling disease–drug connectivity: CEG-based
outlier-sum statistic
In Dr Insight, the detection of CEGs is considered as an important
feature selection step. Statistically significant CEGs have reversed
differential gene expression between the disease and reference drug
data. An effective drug treatment is one that reverts the aberrant
gene expression back to normal levels. Therefore, for each drug in-
stance Yi, we formulate an outlier-sum based statistic to model the
overall disease-drug connectivity as:
OSi ¼
XN
g¼1
zming;i  1z zming;i  za
 
þ zmaxg;i  1z zmaxg;i  za
 
; (5)
where zming;i and z
max
g;i are z-scores transformed from the P-values for
the minimum and maximum statistics. za denotes the z-score that
corresponds to the significance level of a, where a ¼ 0:05. 1zð:Þ is
the indicator function, which returns 1 when the input condition is
Fig. 1. Workflow of Dr Insight. (A) The gene rank list from the differential ana-
lysis (e.g. tumor versus normal) on the disease dataset is used as input. The
reference database contains the gene rank lists (drug instances) from CMap.
(B) Type 1 and type 2 CEGs are identified using order statistics. The bar plot
shows the log P-values of type 1 (blue) and type 2 (red) CEGs. (C) An outlier-
sum score (OS) is calculated for each drug instance and are used to perform
K-S test, where the OS scores of the instances from one drug treatment set
(red x’s) are compared against the rest of the drug instances. (D) Between-
drug and within-drug tests are performed to identify disease-specific drug-
pathway regulations. The node is colored by the average z-scores of CEGs
within a pathway. (E) The output of Dr Insight: a drug-pathway connection
network. The size of the pathways (orange circles) are proportional to their
node degrees
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true; and 0 otherwise. The instance-level outlier sum is an aggrega-
tion of the number of CEGs weighted by their individual concordant
expression score, which can be regarded as a surrogate for overall
disease–drug connectivity. In other words, Dr Insight utilizes the
CEG-based outlier-sum statistic to prioritize potential new drug
treatments for a given disease. To be more specific, for a drug treat-
ment set S; Yi 2 S; 1  i  Ið Þ, such as a group of instances that
are collected from a particular cell line under the same drug perturb-
ation (see Supplementary Material S4.2), we first calculate the
outlier-sum OSi for every individual drug instance in S, and then
compare them with the reference distribution of outlier-sum statis-
tics derived from the entire drug database. We use a two-sample
Kolmogorov–Smirnov (K-S) test to determine whether the OSi from
the instances in drug treatment set S are larger than those from the
rest of the instances in the CMap database. Drug treatment sets with
significant K-S test P-values will be detected as novel repurposing
drug candidates.
2.4 Modeling disease-specific drug–gene connectivity: from CEGs to
drug-target pathways
Computational elicited CEGs are not only a good proxy for disease–
drug connection, but they also provide de novo prediction of poten-
tial disease-specific drug targets. As opposed to the conventional
methods that only include DEGs from the disease data as candidate
drug targets, the elicited CEGs constitutes an optimized gene set to
study drug–gene connectivity by aggregating disease transcriptome
changes with drug perturbation. To further associate biological
functionalities with the detected CEGs so as to attain a system-level
delineation of the disease-specific drug–target interactions, we pro-
vide an interface to perform enrichment analysis of the detected
CEGs on functional gene sets, such as pathways and GO terms from
public databases.
Take pathway analysis as an example. The inputs of the pathway
analysis module include selected CEGs and their corresponding
z-scores for each drug instance. Dr Insight only performs pathway
analysis on significant drugs that are identified at step C of the
workflow (Fig. 1C). In the case study presented in Section 3.5, we
used 222 pathways from the National Cancer Institute PID
(Schaefer et al., 2009) downloaded from Pathway Commons
(Cerami et al., 2011), while the software also provides an interface
so that users can upload their own list of pathways or gene sets. For
pathway1, the instance-level (for the ith drug instance Yi) and drug
treatment set-level (for drug treatment set S) outlier-sum statistic are
given by:
OS1i ¼
X
g21
zming;i  1z zming;i  za
 
þ zmaxg;i  1z zmaxg;i  za
 
(6)
and
OS1S ¼
X
g21
zming;S  1z zming;S  za
 
þ zmaxg;S  1z zmaxg;S  za
 
; (7)
respectively, where the CEG z-scores for drug treatment set S, zming;S
and zmaxg;S , are calculated by:
zming;S ¼ median zming;i Yi 2 S; 1  i  I
n o 
; (8)
and
zmaxg;S ¼ median zmaxg;i Yi 2 S; 1  i  I
	 
 
: (9)
Two statistical tests are used to determine drug-targetable, dysre-
gulated pathways. First, we use the two-sample Kolmogorov–Smirnov
test (K-S test) to perform a ‘between-drug’ significance test by com-
paring the pathway-level outlier-sum OS1i of drug treatment set
S with the rest of the drugs in the database. The P-value of the test
indicates whether genes in pathway1 have a stronger pattern of con-
cordant expression in drug treatment set S compared with other
drugs. Second, for each drug treatment set S, we performed a
‘within-drug’ significance test to compare OS1S of pathway 1 to
OS
1
S of a random pathway
1 of the same size. Fisher’s exact test is
employed to calculate the P-value for within-drug significance.
Finally, we use the maximum of the between- and within-drug P-val-
ues to select statistically significant pathways for each proposed drug
treatment set as a system-level representation of potential drug MoA.
3 Results
3.1 Signature-based connectivity mapping
shows poor agreement in drug detection
using different signature sizes
The determination of query signature has been a long-standing prob-
lem for drug connectivity mapping(Musa et al., 2017; Shigemizu
et al., 2012). However, no existing literature has systematically
studied the impact of signature selection on drug-repurposing
results. Therefore, we applied a range of signature sizes to several
existing drug-repurposing methods, including CMap, sscMap and
NFFinder, to study the consistency of the identified drugs with po-
tential treatment effect. In Figure 2, the Venn diagrams show the
overlap of the identified drugs from five different signature selec-
tions (sizes from 50 to 1000 gene probes, see Supplementary
Material S4.1 for details) for each of the three connectivity-mapping
methods on TCGA breast cancer dataset. Surprisingly for the CMap
method, only five drugs were identified by all signature sizes,
accounting for less than 4% (5/151) of the total identified drugs
(Fig. 2A). On the other hand, as many as 35 drugs detected by size
50 were not reported by any other signature size. Overall, only 58
out of 151 (less than 40%) drugs were commonly identified under
three or more size settings using CMap, indicating a lack of consist-
ency among the identified drugs with different signature sizes. For
sscMap, Figure 2B shows that the signature size had a dramatic ef-
fect in controlling the number of significant drug treatments. When
the signature size was small (50 and 100), sscMap only identified
around a dozen significant drugs, compared with the number that
was dramatically bumped up to over 1000 when the signature size
increased to 600 gene probes. NFFinder showed similar results to
CMap with only 6% (62 out of 1069) of the drugs that were com-
monly identified by all signature sizes (Fig. 2C). The above study
demonstrated an important limitation of the existing signature-
based drug-repurposing methods that the results from different sig-
nature sizes show very poor agreement with one another.
Fig. 2. Overlap of detected drugs (P-value  0.05) using different signature
sizes on the TCGA breast cancer dataset. Five signature sizes at probe level
are selected: 50, 100, 300, 600 and 1000. (A) CMap. (B) sscMap. (C) NFFinder
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To further validate our findings, we applied the three methods to
two additional prostate cancer datasets (Supplementary Fig. S2A).
In general, the results were very consistent with those from the
breast cancer dataset, where the overlap of five signature sizes
remained very small: from no overlap (sscMap on GEO dataset) to
13% (CMap on TCGA dataset). In the best case scenario, the per-
centage of drugs that were commonly detected in at least three sig-
nature settings did not exceed 41% (CMap on TCGA dataset),
further confirming the enormous gap between detected drugs from
these signature-based methods using different query signatures.
Moreover, we also compared the performance of different
signature-based methods when the same input size was used. Also
using TCGA breast cancer dataset as an example, we compared
CMap, sscMap, NNFinder and Cogena at a series of given signature
sizes from 50 to 1000 probes. We see that, with the same size input,
the four different methods resulted in very inconsistent results
(Supplementary Fig. S2B). There were only a small percentage of
common drugs identified by all four methods for signature sizes
from 200 to 1000. No common drugs were identified with small sig-
nature sizes (size 50 and 100). On the other hand, a large percentage
of drugs proposed by each method were unique to itself. These evi-
dences further strengthen our previous argument that not only do
different signature sizes result in inconsistent drug repurposing can-
didates, but also different methods have very poor agreement with
one another when the same gene signatures are used.
3.2 Performance comparison using realistic simulation
We performed simulation studies to evaluate the performance of
Dr Insight compared with several representative signature-based,
two-step drug-repurposing methods, including CMap, sscMap,
NFFinder and Cogena. We first computationally elicited a group of
drugs from the CMap database as a synthetic positive drug set (i.e.
ground-truth drugs) based on cluster analysis. A Monte Carlo strat-
egy was then employed to simulate input disease data using correl-
ation structures trained from known FDA-approved drugs and a
real disease dataset. The above procedure generates ‘realistic’ simu-
lation data by preserving known disease–drug association patterns.
Details about simulation design can be found in Supplementary
Material S5 and Supplementary Figure S3.
We used datasets from the TCGA (breast cancer and prostate
cancer) to generate two simulation studies. For Dr Insight, the entire
synthetic disease rank list was used as input. DEG-derived signatures
of varying sizes were used for querying CMap, sscMap and
NFFinder. For Cogena, we selected query signatures using the crite-
ria of FDR  0.05 and log-fold-change  1, which is recommended
by the original Cogena paper. The overall performance was eval-
uated by the receiver operating characteristic (ROC) curve
(Supplementary Material S6 and Supplementary Fig. S4) and the
areas under the ROC curves (AUCs) were calculated for each
method (Table 1).
CMap, with eight different query signatures, produced an aver-
age AUC of 0.75 that ranged from 0.58 to 0.84 from the eight ROC
curves on TCGA breast cancer-derived simulation dataset. It also
achieved an average AUC of 0.73 (min: 0.66, max: 0.79) in the pros-
tate cancer derived dataset. Similar results were observed for
sscMap, which produced average AUCs of 0.75 (breast cancer) and
0.77 (prostate cancer), with gaps as much as 0.36 (breast cancer,
min: 0.51, max: 0.87) or 0.24 (prostate cancer, min: 0.62, max:
0.86) between the best and the worst performance. Consistent with
what we observed in the previous section, the prediction perform-
ance of CMap and sscMap differed significantly with varying query
signature sizes. The drug predictabilities of NFFinder and Cogena
on both simulation datasets were worse with AUC values no greater
than 0.6. Dr Insight, on the other hand, yielded much higher AUC
values (0.91 and 0.88 on two simulated datasets, respectively) with-
out requiring a pre-determined query signature, which were at least
comparable or even greater than the best performance of all
signature-based methods with any signature size. The simulation
studies validated that the new signature-free, CEG-based drug-
repurposing framework had appealing performance over the con-
ventional signature-based, two-step models to detect disease–drug
associations simulated from known FDA-approved cancer drugs.
Additionally, we also evaluated the false positive rate of
Dr Insight under the null hypothesis. To be more specific, we gener-
ated random disease data through permutations and ran Dr Insight
on these ‘null’ datasets. We repeated this procedure for 50 times and
Fig. 3. Comparing Dr Insight with existing methods on cancer datasets. The
bar plots give the log-transformed enrichment P-values from the five meth-
ods. Multiple enrichment P-values are reported for CMap, sscMap and
NFFinder, which correspond to query signatures of different sizes. The hori-
zontal lines indicate the 0.05 statistical significance level. (A) TCGA breast
cancer dataset. (B) TCGA prostate cancer dataset. (C) GEO prostate cancer
dataset
Table 1. AUC values of five drug-repurposing methods
Methods AUC value for
BRCA-derived
simulation data
avg (min/max)
AUC value for
PRAD-derived
simulation data
avg (min/max)
CMap 0.75 (0.58/0.84) 0.73 (0.66/0.79)
sscMap 0.75 (0.51/0.87) 0.77 (0.62/0.86)
NFFinder 0.54 (0.52/0.57) 0.52 (0.50/0.54)
Cogenaa 0.60 0.56
Dr Insight 0.91b 0.88
aCogena has only one AUC value (per simulation data), which is derived
from the gene signature selected with the recommended criteria by Cogena
paper. bBold values denote the best AUC values across all five methods.
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summarized the number of significant drugs (i.e. false positives)
accordingly (P <¼ 0.05). In general, Dr Insight had an average false
positive rate around 1.15%, indicating good specificity of the
algorithm when there is no association between the disease and
drug data.
3.3 Benchmarking drug prediction performance on
cancer datasets
In addition to the synthetic datasets, we further evaluated the effi-
cacy of Dr Insight to prioritize cancer treatment on public cancer
datasets. Three datasets were included in this study: two TCGA
datasets [breast cancer (Cancer Genome Atlas Network, 2012) and
prostate cancer (Cancer Genome Atlas Research Network, 2015)]
that were previously used to perform realistic simulation, plus one
additional prostate cancer dataset that was downloaded from the
GEO database (Varambally et al., 2005). FDA-approved drugs and
clinical-trial drugs for breast and prostate cancers were collected as
ground-truth drug sets (Supplementary Material S1.2) to benchmark
the performance of the different methods. Similar to the simulation
study, we compared Dr Insight with four other signature-based
methods (CMap, sscMap, NFFinder and Cogena). The gene signa-
tures sized from 50 to 1000 probes were used for the first three
methods and the Cogena gene signature was selected with the crite-
ria of FDR  0.05 and log-fold-change  1. For each of the meth-
ods, we ranked all of the drugs by their detection of P-values and
those with statistical significance stronger than 0.05 were identified
as potential treatments.
We performed enrichment analysis (Fisher’s exact test, see
Supplementary Material S6) to evaluate whether the drug candidates
that were identified by each method had statistically significant
overlap with the ground-truth breast cancer or prostate cancer
drugs. The number of proposed candidate drugs by each method are
listed in Supplementary Tables S5.1–S5.11. Figure 3 gives the bar
plots of log P-values from the enrichment tests of all five methods,
three of which had varying signature sizes. For CMap, sscMap and
NFFinder, an overall conclusion is that their performances to iden-
tify known cancer drugs varied dramatically from one dataset to an-
other. More importantly, large deviations were observed when
different signature sizes were applied. For instance, CMap achieved
its best performance with an enrichment P-value of 0.07 for the
TCGA breast cancer data when the signature size was 100, while for
the GEO prostate cancer data, the top2 CMap performances were
produced by signature sizes of 200 and 800. sscMap and NFFinder
had similar behaviors, which strongly supported our earlier conclu-
sion that the conventional signature-based methods had poor agree-
ment among different signature selections. As for Cogena, though
reasonable empirical criteria for signature selection was applied, its
performance in drug detection was still limited. Cogena had its best
performance on the TCGA breast cancer dataset with an enrichment
P-value of 0.007, yet it failed to retrieve statistically significant
results on the other two datasets. In contrast, Dr Insight obtained
the best performance at identifying known cancer treatments on all
three datasets, without the requirement to pre-select the query signa-
ture. Notably on the TCGA and GEO prostate cancer datasets,
Dr Insight returned significant enrichment P-values of 1.2e-4 and
1.3e-5, respectively. These P-values were significantly better than
the next best performances of a P-value of 0.007 given by Cogena
on the TCGA breast cancer, and a P-value of 4.0e-4 given by
NFFinder (size 100) on the GEO prostate cancer dataset.
Comparable results were observed on two non-cancer datasets: sys-
temic lupus erythematosus data (Banchereau et al., 2016) and
Hepatitis B virus infection data (Yoneda et al., 2016)
(Supplementary Fig. S5). In conclusion, applications on cancer data-
sets verified the robust and exceptional performance of the new
CEG-based, signature-free drug-repurposing model, which achieved
the best performance validated by known cancer drugs.
3.4 CEGs significantly improve drug target prediction
In addition to its superior performance in drug identification, an-
other major contribution from Dr Insight is that it optimizes the
modeling of drug–gene connectivity (i.e. drug target prediction),
using a CEG-based feature selection approach. Under the conven-
tional drug-repurposing framework, people largely rely on DEGs
that are identified from the disease data alone to investigate drug–
gene connectivity, and thereafter for pathway analysis (Shigemizu
et al., 2012). In contrast, Dr Insight uses order statistics to systemat-
ically retrieve CEGs with concordant gene expression change be-
tween disease data and drug treatment data, which, in theory, offers
an optimized set of candidates as potential disease-specific drug
targets.
To test whether the CEG-based methodology substantially
improves the outcome for drug target prioritization, we first col-
lected known drug–target interactions from the STITCH database
as ground truth to benchmark the performance of CEG- and DEG-
based methods on the three public cancer datasets. Figure 4A gives
the bar plots of the percentages of the drugs whose CEGs were over-
represented by known drug–target interactions from the STITCH
database. Details of the percentage calculations can be found in
Supplementary Material S7 and Supplementary Tables S6 and S7.
For the DEG-based method, a range of DEG sizes, from 50 to 1000
probes, were tested. For drugs detected by Dr Insight using the
CEG-based method from the TCGA breast cancer dataset, 15 out of
34 drugs (44%) had significant enrichment on targets collected from
the STITCH database, compared with a maximum performance of
19% of enriched drugs achieved by the DEG-based method. The
performance of the DEG-based method, however, also varied sig-
nificantly from one signature size to another, yielding as much as
5-fold of discrepancy between signature sizes from 50 to 200 probes
and 1000 probes in the case of TCGA breast cancer study. Similarly,
in the other two datasets, the CEG-based method consistently out-
performed the DEG-based method, with 29% and 42% of drugs
that were statistically enriched in the TCGA and GEO prostate can-
cer datasets, respectively, compared with the best performances of
11% and 19% of over-represented ground-truth targets from the
Fig. 4. Percentages of the identified drugs with statistically significant enrich-
ment in known drug targets from drug-target databases. (A) Results from
STITCH database. (B) Results from the CTD database
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DEG-based method. In summary, for all the three cancer studies, the
CEG-based method achieved at least twice the efficacy of existing
methods at retrieving drugs that are enriched in known drug–target
interactions reported by the STITCH database.
In a second validation study, we used drug–target interactions
from the CTD database to test the enrichment of the CEG and DEG-
based methods. Since the drug–target interactions from the CTD data-
base are directed, we also separated the CEGs and DEGs into up- and
down-regulated subsets. Figure 4B gives the percentages of drugs with
statistically significant overlap with known targets in the CTD data-
base. From Figure 4B, we see that the CEG-based method achieved
universally better performance for both up- and down-regulated tar-
get genes in all the three cancer datasets. For instance, for the TCGA
breast cancer dataset, 47% and 38% of the drugs from the CEG-
based method had significant enrichment in up- and down-regulated
genes validated by the CTD database, compared with much smaller
percentages of the significant drugs being identified by the best DEG-
based method (13% and 30%, achieved by size of 300). The results
of the DEG-based method shown in Figure 4 were calculated with
CMap-detected drugs, while the results based on sscMap and
NFFinder-detected drugs are shown in Supplementary Figures S6 and
S7, respectively. The above validation studies strongly supported that,
by incorporating differential gene expression from both disease data
and drug-perturbed data simultaneously, Dr Insight successfully
improved drug–target prediction using CEGs as surrogates for
disease-specific drug–gene connectivity.
3.5 Case study: disease-specific drug–pathway–gene
connections inferred from the TCGA breast cancer
dataset
Finally, we used the TCGA breast cancer dataset as an example to
take a close look at applying Dr Insight to re-engineer novel disease
specific drug–pathway–gene connections (Supplementary Material
S10). Figure 5A gives the drug–pathway interaction network among
10 significant drugs (fulvestrant is not included in the network be-
cause there is no significant pathway identified for it) and 31 path-
ways from the NCI PID pathways (Schaefer et al., 2009)
reconstructed by Dr Insight. The color of the edges between drugs
and pathways represents the type of interaction, i.e. down-
regulation (green) and up-regulation (red).
Five out of the ten identified drugs are in our ground-truth breast
cancer drug list. Among them, fulvestrant is an FDA-approved drug
for treating hormone receptor-positive breast cancer. Also identified
were the HSP90-inhibiting drugs tanespimycin and alvespimycin,
the HDAC-inhibiting drug vorinostat and the anti-proliferation
drug sirolimus, all of which are in advanced stages of clinical trials
for treating breast cancer (Chen et al., 2016). Additionally, five
novel drug treatments for breast cancer were identified, which were
also supported by a number of earlier studies. For instance, 15-delta
prostaglandin J2, a member of cyclopentenone prostaglandins, was
previously reported to induce apoptosis and cell death of breast can-
cer cells (Kim et al., 2009; Pignatelli et al., 2004). More interesting-
ly, the HDAC inhibitor trichostatin A (TSA) was found to have
antitumor activity against breast cancer not only in cell lines but
also in animal models (Liu and Li, 2015; Vigushin et al., 2001).
Previously, pathway analysis in the context of connectivity-
mapping-based drug repurposing typically relies on enrichment test
(e.g. Fisher’s exact test) of input DEGs (Lee et al., 2012; Shigemizu
et al., 2012). One key advantage of Dr Insight’s pathway analysis is
that, derived from the CEGs, the identified pathways are more
enriched in ‘drug actionable targets’ compared with the DEG-based
method. Here, ‘drug actionable targets’ refers to target genes within
a pathway with reversed expression, i.e. ranked top/bottom 10% be-
fore and after drug perturbation. We systematically compared the
percentages of drug actionable targets from Dr Insight (CEG) and
the conventional DEG-based method (Supplementary Material S8).
Supplementary Table S8 shows that pathway results from Dr Insight
were highly enriched in actionable targets (>40%), which was
several-fold higher than the average enrichment by the DEG-based
method.
Through subsequent pathway analysis, we found that several
pathways, such as ATR signaling pathway, PLK1 signaling events
and FOXM1 transcription factor network, were down-regulated by
multiple drugs (Fig. 5A) in our data, suggesting that these pathways
are particularly important for breast cancer tumorigenesis.
Consistent with our discovery, abnormal regulation of the above-
mentioned cell cycle signaling-related pathways have been reported
to cause aberrant breast cell proliferation and apoptosis. Such aber-
ration may lead to tumorigenesis owing to the dysregulation of their
critical component genes, including the DNA damage response kin-
ase genes ATR and ATM (Smith et al., 2010), and the cell cycle reg-
ulating protein modulators such as FOXM1(Hunt et al., 1997). Of
note, the connections between these potential breast cancer drugs
and target pathways have been previously addressed in a number of
studies. The HDAC inhibitor TSA is an example. TSA down-
regulates cyclin genes like CCNB1 and CCND1, and cyclin-
dependent kinases such as CDK4, to arrest cell cycle at G1 or G2/M
phase in breast cancer MCF10A-ras cells (Park et al., 2008). These
cell cycle-related genes are critical functional components of
FOXM1 and PLK1 pathways (Fig. 5B, Supplementary Fig. S8),
which are demonstrated to be down-regulated by TSA in our TCGA
breast cancer study. In addition, Liu et al. reported that TSA pro-
moted cell apoptosis by down-regulating MCM family genes in
colon cancer cells (Liu et al., 2013). While MCM genes and their
highly associated pathways, including ATR signaling pathway
(Fig. 5B) and E2F transcription network (Supplementary Fig. S8),
are identified by Dr Insight as potential TSA targets to treat breast
cancer, our results, together with the discovery by Liu et al. suggest
a possible mechanism through which TSA promotes breast cancer
Fig. 5. Reconstructed breast cancer drug–pathway–gene connections for
TCGA breast cancer data. (A) Reconstructed drug–pathway interaction net-
work. (B) Representative target pathways of TSA and the potential target
genes. Blue hexagons are the pathway genes that are identified as TSA CEGs
and being documented as TSA targets in the CTD database; blue circles are
the novel unregistered TSA CEGs. The networks are visualized using
Cytoscape (Shannon et al., 2003)
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cell apoptosis. In addition to the above-mentioned dysregulated
CEGs that are documented as known targets in drug–target inter-
action databases, Dr Insight also detected dozens of novel drug–
target interactions (Fig. 5B), many of which were supported
by previous literature. An example of novel drug targets is PLK1, a
kinase for efficient G2/S arrest that is known to be directly inhibited
by TSA administration in colon cancer cells (McKenzie et al., 2010).
The above set of evidence demonstrates the ability of Dr Insight to
produce a systematic layout of breast cancer drug interaction net-
work by bridging novel and known target genes with key molecular
pathways such as cell cycle arrest and apoptosis.
4 Discussion
In conclusion, to overcome the limitations of the existing computa-
tional framework, we have developed Dr Insight, which for the first
time ever, offers signature-free, enhanced drug repurposing based on
gene expression data. The genome-wide concordance evaluation by
Dr Insight takes into account the dysregulation of gene expression
from both disease and drug-perturbed data simultaneously, which
renders the statistically significant CEGs as better features to investi-
gate the connections among diseases, drugs and genes. Dr Insight
has broken the computational bottleneck for transcriptome-based
drug discovery, which provides an unbiased first look from novel
redirections of existing drugs toward a systematic understanding of
disease-specific drug MoAs at molecular level.
We have demonstrated using TCGA breast cancer dataset that,
in addition to five FDA-approved drugs or drugs in advanced clinic-
al trials for breast cancer treatment, Dr Insight also identified a few
new drug candidates, which were previously reported to have antitu-
mor functions. The identified pathways further pave the road for in-
depth investigation of these recommended small molecules. The
users may cross-reference their de novo identified disease-specific
drug pathways with existing disease-pathway databases to further
understand the efficacy and the side effects of the proposed drugs.
One such example is given by Chen et al. to study the associations
between pathways and adverse drug reactions (Chen et al., 2015a).
A candidate drug can be flagged when it activates pathways that
lead to adverse effects.
Another important aspect in performance evaluation is to assess
the robustness of the methods against noise in the data. Therefore,
we further performed the sensitivity analysis of Dr Insight, together
with other representative methods on simulation data with con-
trolled noise. Based on the numerical results, we conclude that Dr
Insight can tolerate as much as 60% to even 90% of added noise,
depending on datasets (Supplementary Material S9, Supplementary
Fig. S10).
In addition to the signature-based methods that are compared in
the main text, another simple, yet ‘global’ method that comes natur-
ally to mind for connectivity mapping is the inverse correlation
method. To comprehensively validate the advantage of Dr Insight in
drug repurposing, we also compared Dr Insight with the inverse cor-
relation method on all five disease datasets. The results showed that
Dr Insight consistently outperformed the inverse correlation method
in all studies, although interestingly, the performance of the inverse
correlation method remained quite robust to noise (Supplementary
Material S9, Supplementary Figs S9 and S10).
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